The results indicate the likelihood that some MM tumors have an intrinsic capacity to mount a cyclin D subtype-related compensatory response to trametinib, while other tumors would be less competent and thereby more susceptible to MEK inhibition. Here, MAP2K7 is linked to Miyoshi myopathy.